Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)

Inclusion Criteria: * Adult female 18 years to 45 years of age who experienced GDM within 52 weeks of index pregnancy * Actual BMI \>25 kg/ m2 * Written consent for participation in the study * Patient completed lactation * Dysglycemia (impaired fasting glucose \[IFG}, impaired glucose tolerance \[IGT} or IFG/IGT) and/or ß-cell dysfunction postpartum requiring pharmacological intervention (except type 1 or 2 diabetes) Exclusion Criteria: Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 * History of pancreatitis * Significant cardiovascular, cerebrovascular, renal, or hepatobiliary diseases in the past (viral hepatitis, toxic hepatic damage, jaundice of unknown etiology) * Serum liver enzymes (AST and/or ALT levels) exceeding more than twice normal laboratory values * Uncontrolled hypertension (systolic blood pressure\>150 mm Hg and/or diastolic blood pressure \>90 mm Hg) * Fasting serum triglycerides ≥800 mg/dl at screening. Lipid-lowering medications must have been maintained at the same dose for 3 months prior to enrollment * Hematological profiles considered to be clinically significant * Cholestasis during the past pregnancy * Presence of contradictions for GLP-1 receptor agonist or metformin administration such as allergy or hypersensitivity * Current use of metformin, thiazolidinediones, dipeptidyl peptidase-4 inhibitors or GLP-1 receptor agonist medications. * Use of drugs known to exacerbate…